What is the mechanism of action of the angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mechanism of Action of Sacubitril/Valsartan (ARNI)

Sacubitril/valsartan works through dual mechanisms: sacubitril inhibits neprilysin (an enzyme that degrades beneficial natriuretic peptides), while valsartan blocks the angiotensin II type-1 receptor, simultaneously enhancing protective cardiovascular pathways and blocking harmful ones. 1

Dual Component Action

Sacubitril Component (Neprilysin Inhibition)

  • Sacubitril is a prodrug that is converted by esterases to its active metabolite LBQ657, which inhibits neprilysin (neutral endopeptidase; NEP) 1

  • Neprilysin normally degrades multiple vasoactive peptides, including:

    • Natriuretic peptides (ANP, BNP, CNP)
    • Bradykinin
    • Adrenomedullin
    • Substance P
    • Other vasoactive substances 2, 3
  • By blocking neprilysin, sacubitril increases levels of these beneficial peptides, particularly natriuretic peptides, which produce:

    • Vasodilation
    • Natriuresis (sodium excretion) and diuresis
    • Inhibition of renin and aldosterone release
    • Reduction in blood pressure
    • Favorable effects on cardiac fibrosis and left ventricular hypertrophy 3, 1

Valsartan Component (Angiotensin Receptor Blockade)

  • Valsartan selectively blocks the angiotensin II type-1 (AT1) receptor, preventing angiotensin II from exerting its harmful effects 1
  • This blockade:
    • Prevents vasoconstriction
    • Inhibits angiotensin II-dependent aldosterone release
    • Reduces cardiac remodeling
    • Does not interfere with bradykinin metabolism (unlike ACE inhibitors), which is why the combination avoids the excessive angioedema risk seen with earlier neprilysin inhibitor combinations 3

Synergistic Cardiovascular Effects

The combination addresses two major pathophysiological mechanisms in heart failure simultaneously: activation of the renin-angiotensin-aldosterone system (blocked by valsartan) and decreased sensitivity to natriuretic peptides (enhanced by sacubitril) 2, 3, 1

Observable Pharmacodynamic Effects

When administered, sacubitril/valsartan produces:

  • Increased plasma ANP levels (approximately 4-fold increase) 4
  • Increased plasma BNP (a neprilysin substrate) 1
  • Decreased NT-proBNP (not a neprilysin substrate, reflects improved cardiac function) 1
  • Increased urinary cGMP (marker of natriuretic peptide activity) 1
  • Decreased aldosterone and endothelin-1 1
  • Increased plasma renin activity (evidence of AT1 receptor blockade) 1

Clinical Translation

The dual mechanism translates into superior clinical outcomes compared to ACE inhibitors or ARBs alone. In PARADIGM-HF, this mechanism produced a 20% reduction in cardiovascular death or heart failure hospitalization compared to enalapril 2, 3.

Important Caveat

Neprilysin is a non-selective enzyme with multiple biological targets, including involvement in amyloid-β clearance from the brain. Administration of sacubitril/valsartan increases CSF Aβ1-38 levels, though the clinical relevance remains unknown 1. This broad substrate profile explains both the pleiotropic benefits and the need for monitoring multiple systems.

Related Questions

What are the mechanisms of action of sacubitril/valsartan (angiotensin‑neprilysin inhibitor), beta‑blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors, and how do they work together as the four pillars of heart failure therapy?
What is the optimal management of hypertension in a patient on sacubitril/valsartan (Entresto) and metoprolol who continues to have elevated blood pressure?
Is it safe to prescribe an angiotensin receptor neprilysin inhibitor (sacubitril/valsartan) for a patient with peripartum cardiomyopathy?
In patients with heart failure who are allergic to angiotensin receptor blockers (ARBs), what alternative medication can be used instead of the angiotensin receptor‑neprilysin inhibitor (ARNI) Entresto (sacubitril/valsartan)?
Does Entresto (sacubitril/valsartan) increase B-type natriuretic peptide (BNP) levels?
Why is eplerenone preferred over other mineralocorticoid receptor antagonists (e.g., spironolactone, finerenone) in patients with systolic heart failure?
How should I adjust my levothyroxine (Synthroid) dose given a TSH of 0.0 mIU/L while taking 150 µg daily?
What are the indications, dosing schedule, contraindications, and monitoring recommendations for Sativex (oromucosal spray containing Δ‑9‑tetrahydrocannabinol and cannabidiol) in adults with multiple‑sclerosis‑related spasticity?
How should a comprehensive knee physical examination be performed?
What is the appropriate treatment protocol for a patient with sinus bradycardia (heart rate 57) presenting with an acute anterior wall myocardial infarction?
What are the current blood pressure targets for acute ischemic stroke versus acute intracerebral hemorrhage according to the latest guidelines?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.